A Recombinant Human Pluripotent Stem Cell Line Stably Expressing Halide-Sensitive YFP-I152L for GABA<sub>A</sub>R and GlyR-Targeted High-Throughput Drug Screening and Toxicity Testing

Katharina Kuenzel, Oliver Friedrich and Daniel F. Gilbert

1 Department of Chemical and Biological Engineering, Institute of Medical Biotechnology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; 2 Erlangen Graduate School in Advanced Optical Technologies, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

GABA<sub>A</sub>Rs and GlyRs are considered attractive drug targets for therapeutic intervention and are also increasingly recognized in the context of in vitro neurotoxicity (NT) and developmental neurotoxicity (DNT) testing. However, systematic human-specific GABA<sub>A</sub>R and GlyR-targeted drug screening and toxicity testing is hampered due to lack of appropriate in vitro models that express native GABA<sub>A</sub>Rs and GlyRs. We have established a human pluripotent stem cell line (NT2) stably expressing YFP-I152L, a halide-sensitive variant of yellow fluorescent protein (YFP), allowing for fluorescence-based functional analysis of chloride channels. Upon stimulation with retinoic acid, NT2 cells undergo neuronal differentiation and allow pharmacological and toxicological evaluation of native GABA<sub>A</sub>Rs and GlyRs at different stages of brain maturation. We applied the cell line in concentration-response experiments with the neurotransmitters GABA and glycine as well as with the drugs strychnine, picrotoxin, fipronil, lindane, bicuculline, and zinc and demonstrate that the established in vitro model is applicable to GABA<sub>A</sub>R and GlyR-targeted pharmacological and toxicological profiling. We quantified the proportion of GABA<sub>A</sub>R and GlyR-sensitive cells, respectively, and identified percentages of approximately 20% each within the overall populations, rendering the cells a suitable model for systematic in vitro GABA<sub>A</sub>R and GlyR-targeted screening in the context of drug development and NT/DNT testing.

Keywords: YFP-I152L, glycine receptor chloride channel (GlyR), gamma-aminobutyric acid receptor type-A chloride channel (GABA<sub>A</sub>R), human pluripotent embryonal teratocarcinoma stem cells, NT2 cells, NT2-N cells

INTRODUCTION

GABA type-A receptors (GABA<sub>A</sub>R) and strychnine-sensitive glycine receptors (GlyR) are liganded gated chloride ion channels that mediate inhibitory neurotransmission in the central nervous system (CNS). In adult neurons, GABA<sub>A</sub>R and GlyR ion channels conduct an inhibitory anion current, mainly carried by chloride (Cl<sup>-</sup>) upon activation by γ-aminobutyric acid (GABA) and the amino acid glycine, respectively. In embryonic neurons however, due to a higher intracellular...
chloride concentration compared to adult neurons, receptor activation causes an outward directed, depolarizing and excitatory Cl⁻ flux (Webb and Lynch, 2007). GABA\(_A\)Rs and GlyRs are both members of the pentameric ligand-gated ion channel (pLGIC) family and require five subunits to form a single functional oligomer. For GABA\(_A\)Rs there are 19 genes known (\(\alpha_{1}–6, \beta_{1}–3, \gamma_{1}–3, \delta, \varepsilon, \theta, \pi, \) and \(\rho_{1}–3\)) exhibiting a broad range of heterogeneity and many hundreds of theoretically possible subunit combinations (Olsen and Sieghart, 2009). For GlyRs there are four genes known (\(\alpha_1–3, \beta\)) in humans, exhibiting far less diversity compared to GABA\(_A\)Rs (Lynch, 2009). Each GABA\(_A\)R or GlyR isoform as well as each subunit combination has a unique physiological and pharmacological profile. The subunit combination can change during development, in a tissue-specific manner or as a consequence of pathophysiological events (Lynch, 2004; Webb and Lynch, 2007; Esmaeili and Zaker, 2011; Rudolph and Möhler, 2014; Deidda et al., 2015). Genetic or molecular perturbation of the channels' function has been associated with severe neurological disorders including neuropathic pain (Lian et al., 2012; Xiong et al., 2012; Chen et al., 2014), chronic pain sensitization (Harvey et al., 2004; Zeilhofer, 2005; Lynch and Callister, 2006), hyperrebekplexia (Chung et al., 2010; Bode and Lynch, 2014), epilepsy (Meier et al., 2005; Eichler et al., 2008, 2009; Macdonald et al., 2010), fragile X mental retardation syndrome (D’Hult et al., 2006), learning and memory deficits (Deidda et al., 2015) as well as neurodegeneration (Kang et al., 2015). In addition, GABA\(_A\)Rs and GlyRs are increasingly acknowledged in the context of immunomodulation (Stoffels et al., 2011; Gunn et al., 2015), myotrophic lateral sclerosis (Martin and Chang, 2012) and cancer (Neumann et al., 2004; Cuddapah and Sontheimer, 2011). Therefore, GABA\(_A\)Rs and GlyRs, including individual isoforms as well as the various subunit combinations in their native neuronal environment are increasingly considered highly attractive drug targets for therapeutic intervention (Alexander et al., 2015). Due to their fundamental role in inhibitory neurotransmission GABA\(_A\)Rs and GlyRs are increasingly recognized in the context of neurotoxicity (Suñol et al., 1989; Hall and Hall, 1999; Narahashi, 2002; Vale et al., 2003; Mohamed et al., 2004; Islam and Lynch, 2012) and in vitro neurotoxicity testing (NT) (Talwar et al., 2013; Tukker et al., 2016).

Although GABA\(_A\)Rs and GlyRs play fundamental roles during brain development (Avila et al., 2013, 2014), these receptors have only sparsely been associated with developmental neurotoxicity and developmental neurotoxicity (DNT) testing. This is even more surprising as the incidence of neurological diseases including learning and developmental disorders has increased in recent years (May, 2000; Colborn, 2004; Rauh et al., 2006; Herbert, 2010). At the same time, the number and volume of worldwide registered and traded chemical substances has also increased. There is no doubt that developing brain is particularly vulnerable to damage by chemicals (Rice and Barone, 2000) and evaluation of chemicals for developmental neurotoxicity is critical to human health (Grandjean and Landrigan, 2006, 2014). However, only a very small number of chemicals has been tested for developmental toxicity in recent years (Middaugh et al., 2003; Makris et al., 2009), presumably because the current guidelines for DNT testing exclusively involve animal experiments (OECD, 1997, 2007) that are of poor reproducibility and predictive quality, low in throughput, prohibitively expensive and limited with regard to mechanistic insights into the toxicant's mode of action (Smirnova et al., 2014).

DNT testing is conducted for identification of chemical-induced adverse changes in the structure and function of the developing central nervous system. At present, NT and DNT testing is only officially acknowledged by regulatory authorities when done with standardized in vivo animal test methods and when conducted according to guidelines provided by the Organization for Economic Cooperation and Development (OECD). For example, NT testing involves daily oral dosing of rats for acute, sub chronic or chronic assessments for 28 days, 90 days, 1 year or longer (OECD, 1997). Primary observations include behavioral assessments and evaluation of nervous system histopathology. DNT testing evaluates in utero and early postnatal effects by daily dosing of at least 60 pregnant rats from implantation through lactation. Offspring are evaluated for neurologic and behavioral abnormalities and brain weights and neuropathology are assessed at different times through adulthood (OECD, 2007). The type of exposure (single or repeated dose) and the outcome (lethal or nonlethal; immediate or delayed effects) will result in different classifications for substances under the Globally Harmonized System (GHS).

Since there are various methods available for toxicological profiling of GABA\(_A\)Rs and GlyRs (Gilbert et al., 2009a,b,d; Talwar et al., 2013) these receptors can serve as valuable molecular targets for in vitro developmental neurotoxicity testing (DNT) and provide mechanistic insights into the neurotoxicants or developmental neurotoxins' mode of action. However, systematic screening for potentiating or inhibiting modulators of GABA\(_A\)Rs and GlyRs in the context of drug development and NT/DNT testing is hampered due to lack of appropriate in vitro models. Recombinant expression systems using e.g., human embryonal kidney-derived (HEK293) cells allow systematic large scale screening for GABA\(_A\)R and GlyR modulators in high throughput format (Kruger et al., 2005; Gilbert et al., 2009a,b,d; Talwar et al., 2013; Walzik et al., 2015). Despite recombinant models being successful in the identification of GlyR chloride channel modulators (Balansa et al., 2010, 2013a,b), these systems lack of fundamental neuronal genetic programs and cell intrinsic regulators influencing the functional properties of mature neurons in vivo and are restricted to physiological, pharmacological and toxicological analysis of individual GABA\(_A\)Rs and GlyRs isoforms in isolation. Modulators identified or investigated using recombinant expression systems have been reported to yield contradictive results comparing recombinant systems and native neurons. For example, NV-31 an analog of bilobalide, a major bioactive component of Ginkgo biloba herbal extracts, has been reported to inhibit recombinant GlyRs but to potentiate native hippocampal neuron GlyRs (Lynch and Chen, 2008). Hence, screening data generated using recombinant expression system may be only partially relevant to GABA\(_A\)Rs and GlyRs expressed in vivo and always require time and resource intensive retesting using secondary and individual approaches. Terminally differentiated
neuronal cells of human origin, e.g., primary cells from biopsy samples are rarely available, enable only a limited number of experiments and are typically derived from pathogenic tissue, rendering these cells unsuitable to systematic large-scale screening for modulators of GABA\textsubscript{A}Rs and GlyRs. Neuronal cells of animal origin such as mouse or rat are widely used for studying mammalian inhibitory neurotransmission in general and the physiological properties of GABA\textsubscript{A}Rs and GlyRs in particular but are not optimal for identification of human-specific therapeutic leads or pharmacological probes as well as for GABA\textsubscript{A}R and GlyR mediated neurotoxicity or developmental neurotoxicity as the physiology of animals may strongly differ from human physiology. Stem cells including induced pluripotent stem cell (iPSC) and pluripotent embryonal carcinoma cells provide an enormous potential for both GABA\textsubscript{A}R- and GlyR-targeted drug development and NT/DNT testing as they allow standardized high-throughput \textit{in vitro} screening of a large number of chemicals in maturing and adult human neurons, that is, time, cost and resource-effective.

Human pluripotent NTERA-2 (NT2 or TERA2.cl.SP12) stem cells are increasingly considered as a suitable model for \textit{in vitro} NT and DNT studies (Couillard-Despres et al., 2008; Hill et al., 2008; Laurenza et al., 2013; Pallocca et al., 2013; Stern et al., 2014). Upon exposure to retinoic acid, the cells undergo neuronal differentiation, i.e., mimic the process of differentiation in the developing brain, and are potentially suitable to NT/DNT testing at different developmental stages ranging from non-differentiated stem cells, committed neural progenitors to differentiated neuronal, so called NT2-N cells, and glial cells (Lee and Andrews, 1986; Pleasure et al., 1992; Sandhu et al., 2002; Stewart et al., 2003; Ozdener, 2007; Coyne et al., 2011). Electrophysiological studies and extracellular recordings with NT2-N cells have demonstrated voltage-activated calcium, TTX-sensitive sodium and potassium currents, spontaneous synaptic currents as well as glutamate, N-methyl-D-aspartate (NMDA), GABA and strychnine-sensitive glycine-induced currents (Pleasure et al., 1992; Munir et al., 1996; Neelands et al., 1998; Gao et al., 2004; Coyne et al., 2011; Laurenza et al., 2013) demonstrating that these cells exhibit properties similar to those described in native human neurons thus, making them an excellent experimental model for both GABA\textsubscript{A}R- and GlyR-targeted drug development and NT/DNT testing. Also, a variety of neuronal markers has been reported to be expressed in differentiated NT2-N cells, including β-tubulin type III, MAP-2 and synapsin I (Pleasure et al., 1992; Stewart et al., 2003; Hsu et al., 2014; Saporta et al., 2014; Stern et al., 2014).

To address the limitations of conventional \textit{in vitro} models for GABA\textsubscript{A}R- and GlyR-targeted drug, NT/DNT screening as well as of animal-based \textit{in vivo} NT/DNT testing approaches described above, we aimed to establish a cell line stably expressing YFP-I152L under the control of the human ubiquitin C promoter. The cell line allows fluorescence-based GABA\textsubscript{A}R and GlyR-targeted drug screening and \textit{in vitro} NT/DNT testing at different stages of neuronal maturation. The workflow of cell line generation, stem cell differentiation and functional imaging is shown in Figure 1. Images of recombinant non-differentiated NT2-YFP-I152L stem cells and differentiated NT2-N-YFP-I152L cells as well as the principle of functional imaging using the cells are shown in Figure 2.

**YFP-I152L**, an engineered variant of yellow fluorescent protein (YFP) with greatly enhanced anion sensitivity, is quenched by small anions and is thus suited to reporting anionic influx into cells (Galietta et al., 2001). The fluorescent protein has been successfully applied for structure-function analysis and compound screening with many different chloride channel types (Kruger et al., 2005; Gilbert et al., 2009a,b,d; Balansa et al., 2010, 2013a,b; Chung et al., 2010; Gebhard et al., 2010; Talwar et al., 2013; Walzik et al., 2015).

We further aimed to apply the cell line in concentration-response experiments with GABA and glycine as well as with a selection of chemicals with known toxicity profiles on GABA\textsubscript{A}Rs and GlyRs and to compare GABA and glycine EC\textsubscript{50} and drug IC\textsubscript{50} values with published electrophysiological data and data from fluorescence based functional imaging.

To evaluate the suitability of the \textit{in vitro} model to systematic large-scale functional screening in the context of GABA\textsubscript{A}R- and GlyR-targeted drug development and NT/DNT testing, we intended to quantify the proportion of GABA\textsubscript{A}R- and GlyR-positive cells.

Our \textit{in vitro} model and methodological approach will be applicable within a framework of various individual strategies assessing NT/DNT at different stages during neuronal differentiation as well as to systematic large-scale \textit{in vitro} neurophysiological, pharmacological and toxicological screening with GABA\textsubscript{A}Rs and GlyRs that is time, cost and resource-effective. Furthermore, in the context of \textit{in vitro}-based experimental and analytical approaches for NT/DNT prediction, our methodology can contribute to reduce or even replace animal experiments and to further promote the concept of the 3Rs in biomedicine (Russell and Burch, 1959).

**RESULTS**

We have established a recombinant human pluripotent stem cell line, stably expressing halide-sensitive YFP-I152L under the control of the human ubiquitin C promoter. The cell line allows fluorescence-based GABA\textsubscript{A}R and GlyR-targeted drug screening and \textit{in vitro} NT/DNT testing at different stages of neuronal maturation. The workflow of cell line generation, stem cell differentiation and functional imaging is shown in Figure 1. Images of recombinant non-differentiated NT2-YFP-I152L stem cells and differentiated NT2-N-YFP-I152L cells as well as the principle of functional imaging using the cells are shown in Figure 2.

**Functional Profiling of GABA\textsubscript{A}Rs and GlyRs in Recombinant NT2-N-YFP-I152L Cells**

To assess whether the generated recombinant stem cell line is suitable to chloride imaging and functional profiling of GABA\textsubscript{A}Rs and GlyRs, NT2-YFP-I152L cells were differentiated into neuronal NT2-N- YFP-I152L cells as described in the Methods section and were seeded at defined density of 2 × 10\textsuperscript{4} cells in each well of a 96-well plate. Two days later and approximately 1 h prior to fluorescence imaging, the culture
medium was completely removed and was replaced by 50 μl NaCl control solution. The standard NaCl control solution contained (in mM): NaCl 140, KCl 5, CaCl_2 2, MgCl_2 1, HEPES 10, glucose 10, pH 7.4 using NaOH. The 96-well plate was placed onto the motorized stage of a high-content imaging system and cells were imaged in control solution to record cellular YFP fluorescence in unquenched state. Because YFP-I152L is almost insensitive to chloride, its fluorescence intensity is highest in NaCl solution allowing for optimal focussing into the optical layer of cells. Subsequently, cells were perfused with 100 μl NaI solution containing increasing concentrations of GABA (0.01–100 μM, Figure 3A,B) or glycine (0.1–1000 μM, Figures 3C,D). The NaI test solution was similar to NaCl control solution except that the NaCl was replaced by equimolar NaI. Cells were imaged throughout the complete procedure of agonist perfusion for a total of 30 seconds and with an acquisition rate of 2 Hz. Fluorescence quench was calculated at single cell level by quantitative analysis as described in the Methods section. The principle of functional profiling of ligand-gated chloride channels is depicted in Figures 2D–G. Average time-courses of quench (mean ± SD, n = 10) following the addition of NaI plus the indicated GABA or glycine concentrations are shown in Figures 3A,C, respectively and were constructed by pooling results from wells exposed to different solutions with 10 cells per well. Average agonist dose–response curves constructed from the experiments shown in Figures 3A,C are shown in Figures 3B,D, respectively. Calculated half-maximal activation concentrations (EC_{50}) for GABA (1.1 ± 0.2 μM) and glycine (4.3 ± 0.5 μM) are listed in Table 1 and are overall smaller compared with data from functional CI\(^+\) imaging and electrophysiology previously reported in the literature (see Discussion). However, Hill coefficients (n_H) for GABA (1.8 ± 0.4) and glycine (1.5 ± 0.2) correspond well with data from the literature. Although EC_{50} values measured in this study are overall smaller compared to values from the literature, these data demonstrate that the cell line is suitable for chloride imaging and functional profiling of GABA\_Rs and GlyRs.

**Table 1 | Calculated half-maximal activation concentration and hill coefficients (EC_{50}, n_H) for the used neurotransmitters.**

|          | GABA | Glycine |
|----------|------|---------|
| EC_{50} (μM) | SD | n_H | SD | EC_{50} (μM) | SD | n_H | SD |
| 1.1      | 0.2 | 1.8 | 0.4 | 4.3 | 0.5 | 1.5 | 0.2 |
FIGURE 2 | Images of NT2 and NT2-N cells stably expressing YFP-I152L and principle of functional imaging. (A) Transmission light (left) and fluorescence image (right) of non-differentiated NT2-YFP-I152L cells after 1 day in vitro (DIV) indicating YFP-I152L-expression in most cells of the depicted population. Scale bar 100 µm. (B,C) Transmission light (left) and fluorescence images (right) of differentiated NT2-N-YFP-I152L cells after 35 days in vitro. Cell clusters (B) and neurites (C), highlighted by white arrows in the respective fluorescence micrographs, indicate successful differentiation of NT2-YFP-I152L cells into NT2-N-YFP-I152L cells and demonstrate that stable integration of the YFP-I152L-gene does not interfere with pluripotency of NT2 stem cells and their ability to undergo neuronal differentiation. Scale bar: 100 µm (B) and 30 µm (C). (D,E) Principle of fluorescence-based functional imaging of ligand-gated chloride channels (LGCC) such as GABA<sub>A</sub>Rs and GlyRs. (F) NT2-N-YFP-I152L cells in control solution (NaCl), captured in unquenched state as reflected in the schematic drawing shown in (D). (G) NT2-N-YFP-I152L cells in quenched state, recorded upon addition of test solution (NaI) supplemented with the GlyR agonist glycine and as reflected by (E). Scale bar: 50 µm.

n = 10) drug dose–responses are shown in Figures 4, 5. Calculated half-maximal inhibition concentration (IC<sub>50</sub>) for the tested chemicals are summarized in Table 2 and indicate that the recombinant cell line is suitable to GABA<sub>A</sub>R and GlyR-targeted toxicological profiling and identification of ion channel-specific drugs.

Quantification of the Proportion of GABA<sub>A</sub>R and GlyR Positive NT2-N-YFP-I152L Cells

The applicability of the established recombinant in vitro model for high-throughput GABA<sub>A</sub>R and GlyR-targeted screening in the context of lead identification and NT/DNT testing strongly depends on the proportion of GABA<sub>A</sub>R and GlyR positive NT2-N cells in the whole cell population. A very small percentage of GABA<sub>A</sub>R and GlyR expressing NT2-N cells requires a large number of individual experiments including technical and biological replicates to be conducted in order to obtain statistically sound results, potentially compromising the usability of the established cell line for the envisioned application. To obtain a robust estimate of the proportions of GABA<sub>A</sub>R and GlyR positive NT2-N-YFP-I152L cells in the overall cell population, we calculated the percentage of cells per image indicating a fluorescence quench of at least 20% upon application of saturating GABA or glycine concentration. The threshold of 20% fluorescence quench was chosen because, from our experience, any measured cellular fluorescence change within a range of −20

| Drug          | GABA (IC<sub>50</sub>, SD) | Glycine (IC<sub>50</sub>, SD) |
|---------------|-----------------------------|-------------------------------|
| Strychnine (nM) | –                           | 17.2 (7)                      |
| Picrotoxin (µM) | 5.8 (0.9)                   | 1.1 (0.2)                     |
| Fipronil (µM)  | 10.8 (5.8)                  | 1.5 (0.9)                     |
| Lindane (nM)   | –                           | 78.1 (32.6)                   |
| Bicuculline (µM) | 1.1 (0.3)                   | 13.4 (2.5)                    |
| Zinc           | –                           | –                             |

TABLE 2 | Calculated half-maximal inhibition concentration (IC<sub>50</sub>) for the tested chemicals indicating that the recombinant cell line is suitable to GABA<sub>A</sub>R and GlyR-targeted toxicological profiling and identification of ion channel-specific drugs.
to 20% reflects biological noise typical to the employed assay. As a starting point toward analyzing the proportion of GABA$_A$R and GlyR-positive cells we segmented the images of a total of 24 individual experiments from two different differentiation batches (GABA$_A$R, batch #1: $n = 7$, batch #2: $n = 6$; GlyR, batch #1: $n = 6$, batch #2: $n = 5$) using a modified version of DetecTIFF$^\text{©}$ software (Gilbert et al., 2009c) employing two individual sets of parameters for the identification of small neuronal NT2-N-YFP-I152L and larger non-neuronal NT2-YFP-I152L cells. Figure 6A shows a representative fluorescence micrograph of large NT2-YFP-I152L and small NT2-N-YFP-I152L cells, highlighted with white and gray arrows, respectively. Exemplary segmentation masks created from the image shown in Figure 6A for quantitative analysis of fluorescence intensity and calculation of “% fluorescence quench” in small neuronal NT2-N-YFP-I152L cells and large non-neuronal cells are depicted in Figures 6B,C. The average cell size (in pixel, mean ± SD) of GABA or glycine-exposed small and large cells calculated from two independent differentiation batches is shown in Figure 6D and is as follows: GABA-exposed small cells: 177 ± 94 (batch #1, $n = 1869$) and 152 ± 89 pixel (batch #2, $n = 2560$), GABA-exposed large cells: 1369 ± 760 (batch #1, $n = 1216$) and 1228 ± 709 pixel (batch #2, $n = 1371$); glycine-exposed small cells: 163 ± 93 (batch #1, $n = 1631$) and 158 ± 92 pixel (batch #2, $n = 1071$); glycine-exposed large cells: 1356 ± 757 (batch #1, $n = 1212$) and 1316 ± 752 pixel (batch #2, $n = 828$). In a next step, we calculated the percentage of cells per image indicating a fluorescence quench of at least 20% upon application of saturating GABA and glycine concentration (see histogram in Figure 6E) that is as follows: GABA-exposed small cells: 28 ± 13 (batch #1, $n = 7$) and 32 ± 12 % (batch #2, $n = 6$), GABA-exposed large cells: 3 ± 1 (batch #1, $n = 7$) and 6 ± 2% (batch #2, $n = 6$); glycine-exposed small

![FIGURE 3](image-url) GABA and glycine-induced fluorescence quench in NT2-N cells stably expressing YFP-I152L measured using a fluorescence microscope. (A,C) Averaged time-courses of quench following the addition of NaI plus the indicated GABA or glycine concentrations, respectively. (B,D) Averaged GABA and glycine concentration–responses measured from the data in (A,C), respectively, 30 s after receptor activation. In this and the subsequent figures, “% fluorescence quench” is defined as ($F_{\text{init}} - F_{\text{final}}$) × 100 / $F_{\text{init}}$, where $F_{\text{init}}$ and $F_{\text{final}}$ are the initial and final values of fluorescence, respectively. All data are given as mean ± SD (n = 10).
Applicability of the established in vitro model for pharmacological and toxicological evaluation of GABA_A_R modulators.

(A–F) Averaged dose-responses (mean ± SD, n = 10) of the chemicals strychnine, picrotoxin, fipronil, lindane, bicuculline, and zinc, demonstrating the applicability of the cell line for GABA_A_R-targeted screening in the context of drug development and NT/DNT testing. 1 µM GABA concentration, basically reflecting GABA half-maximal activation concentration, was used in these experiments.

DISCUSSION

For the sake of feasibility, throughput and cost reasons, GABA_A_R and GlyR-targeted screening is typically conducted in non-neuronal recombinant expression systems assessing individual GABA_A_Rs and GlyRs isoforms in isolation. Such expression systems usually also lack fundamental neuronal genetic programs and cell intrinsic regulators of mature neurons in vivo. The initial benefit is often compromised by subsequent time-consuming and cost-intensive re-screens for validation and specificity-evaluation of potential GABA_A_R and GlyR-modulators. In the context of neurotoxicity (NT) or developmental neurotoxicity (DNT) testing, GABA_A_Rs and GlyRs can serve as molecular targets and can contribute to deciphering the molecular mechanisms of toxic effects. However, so far there are no suitable in vitro models available which comprehensively reflect the complex situation of the central nervous system in vivo and NT/DNT testing is still solely based on animal experimentation that is morally questionable, low in throughput, expensive and of rather poor predictive quality. To address these issues, we have established a recombinant human pluripotent stem cell line, stably expressing YFP-I152L that is advantageous for GABA_A_R and GlyR-targeted screening in the context of lead identification and drug development as well as for NT/DNT testing for several reasons. First, the recombinant cell line allows functional profiling of GABA_A_Rs and GlyRs in neuronal environment, providing fundamental neuronal genetic programs and cell intrinsic regulators critical to reflecting the functional properties of the central nervous system.
Quantification of the proportions of \( \text{GABA}_A \)R and GlyR-positive NT2-N-YFP-I152L cells. (A) Representative fluorescence micrograph of NT2-N-YFP-I152L cells in differentiation culture used for functional imaging experiments. (B,C) Exemplary segmentation masks created from (A) for quantification of “% fluorescence quench” in small NT2-N-YFP-I152L cells (gray arrows, B) and large non-neuronal cells (white arrows, C), respectively. (D) Comparative analysis of the average cell size (in pixel) of \( \text{GABA}_A \)R and GlyR-positive small neuronal and large non-neuronal cells quantified from two independent differentiation batches each. (E) Comparative analysis of the average percentage of small NT2-N-YFP-I152L and large non-neuronal cells, responding with at least 20% fluorescence quench upon exposure to saturating GABA or glycine concentration, respectively. Approximately one third of the small cell population is represented by \( \text{GABA}_A \)R and GlyR-positive cells, equaling about 20% of the overall population of cells. These data indicate a small proportion of \( \text{GABA}_A \)R and GlyR-expressing cells that is stable between individual experiments and differentiation batches, further highlighting the applicability of the established \textit{in vitro} model for systematic \( \text{GABA}_A \)R and GlyR-targeted high-throughput pharmacological and toxicological screening in the context of drug development and NT/DNT testing. Scale bar: 200 \( \mu \text{m} \).

We exposed the cell line to GABA or glycine and demonstrated that the \textit{in vitro} model is suitable to functional imaging of both \( \text{GABA}_A \)Rs and GlyRs. Despite the fact that Hill coefficients compare well with data from the literature, the calculated half-maximal activation concentration for GABA and glycine is overall smaller compared to \( \text{EC}_{50} \) concentrations previously measured in NT2-N cells using whole cell patch clamp electrophysiology (Neelands et al., 1998; Gao et al., 2004; Gao and Greenfield, 2005; Coyne et al., 2011). Although it is difficult to isolate the reason for this without directly comparing concentration-response data from the same cells generated with different methodologies, the apparent high GABA and glycine sensitivities may have been caused by the relatively long incubation time in agonist solution, i.e., the time between application of the agonist and quantification of the fluorescence intensity (30 s). Furthermore, we have previously observed differences in glycine \( \text{EC}_{50} \), i.e., increased sensitivity for glycine, in recombinantly expressed \( \alpha_1, \alpha_2, \) and \( \alpha_3 \) GlyRs, assessed with the fluorescence-based assay vs. patch clamp electrophysiology (Talwar et al., 2013).

We used the recombinant \textit{in vitro} model in a case study with the drugs strychnine, picrotoxin, fipronil, lindane, bicuculline and zinc. The imaging data indicate that YFP-I152L-expressing NT2-N cells are applicable to \( \text{GABA}_A \)R and GlyR-targeted toxicological profiling and identification of ion channel-specific drugs. The drug strychnine specifically inhibited glycine but not GABA-induced anion-influx with average \( \text{IC}_{30} \) values that correspond very well with results measured...
by either electrophysiological or equilibrium $[^3]H$-strychnine displacement studies using recombinantly expressed homomeric wildtype α1 GlyRs and variants (Lynch et al., 1997; Vafa et al., 1999). Also, concentration-response experiments with picrotoxin, a standard pharmacological tool for identifying the presence of β-subunits in recombinant and native GlyRs (Lynch, 2004) revealed half-maximal inhibition concentrations and slope values for glycine and GABA-induced anion influxes, that correspond well with results measured by patch clamp electrophysiology in recombinantly expressed homomeric α2 GlyR (Wang et al., 2007) as well as in human pluripotent stem cell-derived neurons (James et al., 2014), respectively. The alkaloid is known to strongly inhibit GABA$_\text{A}$Rs at low micromolar concentrations, whereas GlyRs in vivo are considered much less sensitive (Lynch, 2004). However, we observed a reversed sensitivity sequence with a picrotoxin-sensitivity of GlyR that is approximately 5-fold higher compared to GABA$_\text{A}$Rs. As it has been reported that αβ-heteromeric GlyRs were less sensitive to picrotoxin-inhibition than were α-homomeric GlyRs (Pribilla et al., 1992) we speculate that NT2-N-YFP-I152L cells predominantly express α-homomeric GlyR rather than αβ-heteromeric GlyRs, although this is no explanation for the reversed picrotoxin-sensitivities of GlyRs and GABA$_\text{A}$Rs. Bicuculline, a purported selective antagonist of the GABA$_\text{A}$ receptor, inhibited the GABA-induced fluorescence quench with a half-maximal inhibition concentration similar to values revealed from rat primary neurons by whole cell electrophysiological recordings (Kumamoto and Murata, 1995). Bicuculline also inhibited glycine induced $I^-$ influx in NT2-N-YFP-I152L cells with about 10-fold lower sensitivity compared to GABA-dependent anion influx, highlighting its specificity to GABA$_\text{A}$R on the one hand, but also confirming previous reports on its inhibitory action assessed in both recombinantly expressed (Sun and Machu, 2000) and native glycine receptors (Bhattarai et al., 2016) on the other hand. The IC$_{50}$ value for glycine-induced fluorescence quench revealed in presence of increasing concentration of the insecticide lindane is about one order of magnitude smaller compared to electrophysiological recordings from recombinantly expressed GlyRs (Islam and Lynch, 2012). These data suggest that NT2-N-YFP-I152L cells predominantly express homomeric GlyRs as lindane has proven to selectively inhibit homomeric but not heteromeric GlyRs (Islam and Lynch, 2012; Talwar et al., 2013). This conclusion is further supported by the above mentioned high picrotoxin-sensitivity of GlyRs. Surprisingly, lindane showed no dose-dependent inhibitory activity on GABA-induced anion influx, although lindane-sensitivity of GABA$_\text{A}$Rs has been reported by many studies conducted in various culture models and cell types (Narahashi, 1996; Ogata et al., 1988; Vale et al., 2003). A study conducted by Belelli et al. (1999) demonstrated no effect on GABA-evoked currents mediated by anesthetic-insensitive wild-type GABA receptors composed of the (rho 1) subunit (Belelli et al., 1999), suggesting expression of GABA$_\text{A}$ rho 1 receptor in the examined NT2-N-YFP-I152L cells. Indeed there are a number of studies indicating profound changes in subunit expression and pharmacology during neuronal differentiation—similar to developmental changes in GABA$_\text{A}$R occurring in neurons of the developing central nervous system—and demonstrating a large variety of neurotransmission phenotypes of non-differentiated NT2 and differentiated NT2-N cell in vitro (Neelands et al., 1998, 1999; Guillemaing et al., 2000). This question however was not further evaluated in the present study. Fipronil, a broad-spectrum insecticide, inhibited both GABA and glycine induced anion influx in NT2-N cells with sensitivities that correspond very well to results measured by patch clamp electrophysiology in recombinantly expressed GlyRs and GABA$_\text{A}$R (Ratra et al., 2001; Li and Akk, 2008; Islam and Lynch, 2012). Zinc is widely recognized as a modulator of both, GABAAR and GlyR (Smart et al., 1994). For GlyRs, potentiation as well as inhibition of glycine-activated currents by low (<10 $\mu$M) and high concentrations (>100 $\mu$M) of zinc, respectively has been reported (Harvey et al., 1999). For GABAARs, inhibition has been shown at concentrations >10 $\mu$M (Kumamoto and Murata, 1995). Although we observed a minor increase of a glycine-induced fluorescence quench (Approximately 10%) in presence of 1 and 10 $\mu$M zinc, this effect is not significant. In contrast, zinc-dependent inhibition was observed at concentrations >100 $\mu$M for both GABA and glycine-induced anion influx, confirming previous reports on zinc-sensitive GABA-induced currents recorded from NT2-N cells (Gao et al., 2004). The zinc IC$_{50}$ could not be calculated due to a too small range of applied concentrations but presumably exceeds 1 mM, suggesting the presence of γ subunits which have shown to confer zinc insensitivity to αβ GABA$_\text{A}$Rs (Smart et al., 1991).

We quantified the proportion of GABA$_\text{A}$R and GlyR positive NT2-N-YFP-I152L cells based on images of the cells and we identified a percentage of approximately 20% of cells expressing GABA$_\text{A}$Rs and GlyRs, respectively. Despite the fact that the proportion of glycine and GABA sensitive cells are comparable, it cannot be concluded from our data whether the cells are simultaneously sensitive to both glycine and GABA or respond to either of the neurotransmitters. Although the calculated proportions have proven stable between different batches of differentiation cultures, the total percentage of GABA$_\text{A}$R and GlyR positive NT2-N-YFP-I152L cells is not optimal for plate reader, i.e., photomultiplier or cell population-based screening, that typically requires a high number of reacting, e.g., GlyR or GABA$_\text{A}$R-positive cells and allows experimentation in high-throughput screening mode. If desired or required, the proportion of NT2-N-YFP-I152L cells may be increased by size-exclusion filtering using e.g., a simple nylon filter of defined mesh size or even more sophisticated cell sorting approaches. As highlighted by gray and white arrows in the fluorescence micrograph depicted in Figure 6A and the histogram shown in Figure 6D, NT2-N cells are much smaller compared to non-neuronal cells, presumably facilitating size-dependent population-increase of NT2-N cells. Despite the fact that plate reader-based screening allows experimentation in high or even ultra-high-screening mode it is disadvantageous with regard to cellular heterogeneity. Cultures of NT2 cells have been reported to express a large variety of non-neuronal and neuronal phenotypes (Guillemaing et al., 2000), as we have shown in the case study using drugs with known and partly GABA$_\text{A}$R and...
GlyR-specific pharmacological and toxicological profiles. Besides their neuronal properties and human origin, the heterogeneity of NT2-N cell cultures is probably one of the most important advantages over homogeneous, e.g., recombinant expression systems, as it reflects the in vivo situation to a much higher extent than simplifying in vitro models. Thus, microscopy-based high-content imaging of NT2-N cells, evaluating the physiological pharmacological and toxicological properties at single cell level, and in the context of cellular heterogeneity, is likely to be the optimal approach for systematic GABA<sub>R</sub> and GlyR-targeted drug screening as well as NT/DNT testing.

To confirm the validity of the morphology or size-based selection criterion, we conducted functional imaging experiments with non-treated NT2-YFP-I152L stem cells and quantified the average cell size as well as the percentage of stem cells, responding with at least 20% fluorescence quench upon exposure to saturating GABA or glycine concentration, respectively (see Supplementary Figure S1). The average cell size (pixel), calculated from two individual experiments each (see Supplementary Figure S1C) is comparable between experiments (GABA, replicate #1: 397 ± 254 pixel, n = 650 cells, replicate #2: 385 ± 252 pixel, n = 547 cells; glycine, replicate #1: 403 ± 243 pixel, n = 589, replicate #2: 400 ± 256 pixel, n = 654) and differs from the size of small and large cells, respectively, as indicated in Figure 6D. The percentage of non-treated NT2-YFP-I152L stem cells, responding with at least 20% fluorescence quench upon exposure to 1 mM saturating GABA (replicate #1: 0.62%, replicate #2: 0.37%) or glycine (replicate #1: 0.68%, replicate #2: 0.92%) concentration, respectively (see Supplementary Figure S1D), also differs considerably from data obtained with retinoic acid-exposed NT2-N-YFP-I152L cells. These data clearly demonstrate that the morphology, e.g., the size, as well as the functional properties, i.e., the sensitivity to GABA or glycine, vary between non-treated stem cells and NT2-YFP-I152L differentiation cultures containing small neuronal and large non-neuronal cells and confirming the validity of the employed size-based selection criterion.

We have previously published a method allowing for assessment of ligand-gated ion channels in the context of cellular heterogeneity that is based on progressive receptor activation and iterative fluorescence imaging (Talwar et al., 2013). This method could easily be adapted for application with the established in vitro model and has the power to deliver imaging data of unsurpassed functional content presumably outranging any other existing technique for assessing physiological properties of ion channels with regard to throughput.

Due to the fact that our method is based on microscopic evaluation using a single fluorescence indicator, it allows additional fluorescence or luminescence-based markers to be implemented for multiplexing, such as ion or pH-sensitive probes e.g., for parallel analysis of further ion channels or transporters, to assess the activity of intracellular, e.g., toxicity-relevant signaling pathways, or for mapping cellular morphology to functional phenotypes.

It is important to mention that the applicability of the cell line as well as the experimental approach depends on the proteins to be evaluated and targeted, on the individual experimental setup, the available instrumental infrastructure and the biological question to be assessed. While this work focuses on functional profiling and GABA<sub>R</sub> and GlyR-targeted drug screening as well as neurotoxicity and developmental neurotoxicity, our in vitro model and methodological approach could also be adapted for other proteins and strategies, such as RNAi or combined compound and RNAi screening, for single-endpoint or time-resolved functional expression analysis or for approaches using overexpression libraries. Altogether, this work contributes to furthering the applicability of cell-based high-throughput functional screening and provides a means for large-scale characterization of neuronal proteins in the context of in vitro-based NT/DNT prediction thus, promoting a systems-level understanding of human physiology in homeostasis and disease.

**METHODS**

**Pharmacological Reagents**

Glycine, GABA, strychnine, picrotoxin, fipronil, lindane, zinc chloride and bicuculline were obtained from Sigma. Stock solutions of glycine (1 M), GABA (1 M) and zinc chloride (1 M) were prepared in water, strychnine (10 mM), picrotoxin (100 mM), fipronil (30 mM), lindane (30 mM) and bicuculline (100 mM) were dissolved in dimethylsulphoxide (DMSO). All stocks were frozen at −20°C. From these stocks, solutions for experiments were prepared on the day of recording.

**Reagents for Differentiation of NT2 Pluripotent Stem Cells**

Retinoic acid and poly-D-lysine (PDL) were obtained from Sigma. Retinoic acid was prepared as 100 mM stock in DMSO. Uridine was prepared as 100 mM stock in DMSO. Uridine was prepared as 100 mM stock in water. These stocks were kept at −80 to −20°C. PDL was prepared as 10x stocks in water and stored at 4°C. Solutions for differentiation cultures were prepared freshly at the days of experimentation.

**Molecular Constructs**

The regulatory region of the human ubiquitin C promoter (1204 bp) was amplified by PCR, the vector pFUGW (Addgene) was used as the template as well as specific primers (Invitrogen). The fragment was then inserted into the promoterless vector pDsRed2-1 (Clontech). PCR of the YFP-I152L gene (720 bp) was performed using vector pCDNA3.1-YFP-I152L (Invitrogen) as a template and specific primers (Invitrogen). The YFP-I152L-coding construct was kindly provided from Prof. Joe Lynch (Queensland Brain Institute, The University of Queensland, Brisbane, Australia). After removing the sequence of the red fluorescent protein from the vector phuUbC-DsRed2, YFP-I152L was sub-cloned into the vector. The expression of YFP-I152L is under the control of the constitutive active human ubiquitin C promoter, the plasmid carries the neomycin resistance gene for the selection with the antibiotic geneticin.

**Cell Line**

Human pluripotent teratocarcinoma NT2 cells (NTERA-2 cl.D1, CRL-1973<sup>TM</sup>) were purchased from *The American Type Culture Collection* (ATCC).
Generation of Stable Cell Line

For generating a cell line stably expressing YFP-I152L, NT2 stem cells were seeded into 60 mm culture dishes (TPP) at a density of 5 × 10^5 cells and were incubated at standard conditions overnight. The next day, cells were transfected with ubiquitin-YFP-I152L-encoding vector using the calcium phosphate precipitation method. YFP-I152L-positive cells were selected over 5 weeks with 0.5 mg/ml geneticin (Roth, Germany). The geneticin concentration had previously been examined in a concentration-response experiment with 0.1–1.0 mg/ml geneticin by measuring the fluorescence intensity of Hoechst 33342 stained (1 µM) cells exposed to geneticin for 48 h in 96-well plate format using a VICTOR X4 plate reader (Perkin Elmer). The kill curve for evaluation of the geneticin concentration is shown in Figure 1A, subpanel #2. Geneticin-selected NT2-YFP-I152L cells with strongest fluorescence signal were enriched by flow cytometry (FACS, approximately top 30%, see Figure 1A, subpanel #3) in a single step. Enriched cells were maintained in geneticin-supplemented medium at the above mentioned concentration until initiation of the differentiation procedure. Recombinant cells were used over a large range of passages between passage number 15 and 50, without noticeable decline in YFP-I152L fluorescence intensity.

Cell Culture

Cells were maintained in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS, Biochrom) and penicillin (100 U/ml)/streptomycin (100 mg/ml) (Invitrogen) and were cultured for 5 weeks at 37°C, 5% CO2 in a humidified incubator according to standard procedures. Cells were passaged every 2–3 days and used in differentiation cultures when approximately 80–90% confluent.

Differentiation Culture

We have previously developed an optimized method for neuronal differentiation of human pluripotent NT2 stem cells in monolayer cultures. In brief, NT2 cells were seeded at a defined density into PDL coated 60 mm dishes (TPP) in standard culture medium supplemented with 10% FBS and penicillin (100 U/ml)/streptomycin (100 mg/ml) and 10 µM RA and were cultured for 5 weeks at 37°C, 5% CO2 in a humidified incubator. In the second week, 10 µM uridine was added to the media.

Preparation of Cells for Experiments

Following retinoic acid treatment, cells were replated into T25 flasks and cultured overnight at standard conditions. The next day, NT2-N-YFP-I152L cells located on top of non-differentiated cells were removed by tapping and were seeded at a density of 2 × 10^6 into the wells of a BD Matrigel™ matrix (BD) coated 96-well plate. Cells were used in functional imaging experiments 48 h later.

Preparation of Imaging Experiments

Approximately 1 h prior to commencement of experiments culture media in 96-well plates was removed manually and was replaced by 50 µl standard control solution, which contained (in mM) NaCl 140, KCl 5, CaCl₂ 2, MgCl₂ 1, HEPES 10, and glucose 10 (pH 7.4, NaOH) upon washing the cells once in 50 µl standard control solution. The NaI test solution was similar in composition to NaCl control solution except the NaCl was replaced by equimolar NaI. For imaging experiments the agonist NaI test solution was supplemented with 1 mM glycine or GABA and was serially diluted with NaI test solution to obtain agonist solutions containing 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100 µM final GABA or 0.1, 0.3, 1, 3, 10, 30, 100, 300 and 1000 µM final glycine concentration. For antagonist concentration-response experiments, the control solution was supplemented with 1 µM GABA or 3 µM glycine and increasing concentrations of either of the drugs strychnine (100 pM–10 µM), picrotoxin (1 nM–100 µM), fipronil (1 nM–100 µM), lindane (1 nM–100 µM), bicuculline (1 nM–100 µM) and zine (10 nM–1 mM). All drugs were diluted from stocks at the day of the experiment and experiments were conducted at room temperature.

Imaging Infrastructure

The 96-well plate was placed onto the motorized stage of a high-end long-term imaging system (Nikon Eclipse Ti, Nikon, Japan) and was imaged with a 10x objective (CFI Plan Fluor DL 10X C, 5% CO2 in a humidified incubator. Images were acquired at 512 × 512 pixel resolution with a sCMOS camera (NEO, Olympus, Japan) was used to excite and detect YFP fluorescence signal. Fluorescence was imaged by a sCMOS camera (NEO, Andor, Ireland) and digitized to disk onto a personal computer (Dell Precision T3500, Dell, USA) with Windows 7 operating system (Microsoft Corporation, USA). The primary resolution of the camera was 2560 × 2160 pixel, although images were binned (2 × 2), resulting in a resolution of 1280 × 1080 pixel. Each image typically contained 350–700 cells. The CCD image acquisition rate was 2 Hz.

Imaging Experiments

The experimental protocol involved imaging each well for 30 s at 2 Hz acquisition rate capturing the initial fluorescence intensity in the control situation as well as the test situation upon receptor activation, respectively. Liquid handling was performed manually.

Single Cell-Based Quantitative Image Analysis

Cells depicted in fluorescence micrographs were selected manually based on strongest quench for low and intermediate concentrations and based on cell morphology in experiments where high drug concentrations were applied. Registered images of fluorescent cells were segmented and quantitatively analyzed using NIS-Elements software (Nikon, Japan). The fluorescence signal of identified cells was measured in images acquired before and after the addition of agonist solution as the mean of all pixel values within the area of a cell. % fluorescence quench\(^{\text{a}}\) in chloride imaging experiments is defined as

\[
\text{\% fluorescence quench} = \left( \frac{F_{\text{init}} - F_{\text{final}}}{F_{\text{init}}} \right) \times 100
\]

where \(F_{\text{init}}\) and \(F_{\text{final}}\) are the initial and final values of fluorescence, respectively.
Calculation of Concentration-Response Relationships

Individual concentration responses were constructed by pooling results from ten cells in one well exposed to agonist solution. Concentration-response relationships were fitted with the following equation:

\[ F = \frac{F_{\text{max}} - F_{\text{min}}}{1 + \left( \frac{[\text{Agonist}]}{EC_{50}} \right)^{nH}} + F_{\text{min}} \]

where \( F \) is the fluorescence corresponding to a particular agonist concentration, \([\text{Agonist}]\); \( F_{\text{min}} \) and \( F_{\text{max}} \) are the minimal and maximal fluorescence values, respectively; \( EC_{50} \) is the concentration that elicits half-maximal activation; and \( nH \) is the Hill coefficient. Curve fits were performed using a least squares fitting routine (Origin 7G, OriginLab Corporation). All averaged results are expressed as mean ± SD.

Quantification of the Proportion of GABA_{AR} and GlyR-Positive Cells

Images of fluorescent cells were segmented and quantitatively analyzed using a modified version of DetectTIFF® software (Gilbert et al., 2009c). In brief, images were segmented using an iterative size and intensity-based thresholding algorithm and the fluorescence signal of identified cells was calculated as the mean of all pixel values within the area of a cell.

Data Analysis and Visualization

Imaging data were annotated in Microsoft Excel and analyzed using Origin 7G (OriginLab Corporation).

AUTHOR CONTRIBUTIONS

KK, OF, and DG conceived the project. KK conducted experiments. KK and DG analyzed the data. KK and DG wrote the paper. All authors commented and agreed on the manuscript.

ACKNOWLEDGMENTS

The authors gratefully acknowledge funding of the Staedler Stiftung, Bavarian Equal Opportunities Sponsorship—Förderung von Frauen in Forschung und Lehre (FFL)—Promoting Equal Opportunities for Women in Research and Teaching and the Erlangen Graduate School in Advanced Optical Technologies (SAOT) by the German Research Foundation (DFG) in the framework of the German Excellence Initiative. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fnmol.2016.00051

REFERENCES

Alexander, S. P. H., Peters, J. A., Kelly, E., Marrion, N., Benson, H. E., Faccenda, E., et al. (2015). The concise guide to PHARMACOLOGY 2015/16: ligand-gated ion channels. Br. J. Pharmacol. 172, 5870–5903. doi: 10.1111/bph.13350

Avila, A., Vidal Pía, M., Dear, T. N., Harvey, R. J., Rigo, J.-M., and Nguyen, L. (2013). Glycine receptor α2 subunit activation promotes cortical interneuron migration. Cell Rep. 4, 738–750. doi: 10.1016/j.celrep.2013.07.016

Avila, A., Vidal, P. M., Tielsens, S., Morelli, G., Laguesse, S., Harvey, R. J., et al. (2014). Glycine receptors control the generation of projection neurons in the developing cerebral cortex. Cell Death Differ. 21, 1696–1708. doi: 10.1038/cdd.2014.75

Balansa, W., Islam, R., Fontaine, F., Piggott, A. M., Zhang, H., Webb, T. I., et al. (2010). Iricinalactams: subunit-selective glycine receptor modulators from Australian sponges of the family Ircinidae. Bioorg. Med. Chem. 18, 2912–2919. doi: 10.1016/j.bmc.2010.03.002

Balansa, W., Islam, R., Fontaine, F., Piggott, A. M., Zhang, H., Xiao, X., et al. (2013a). Sesterterpene glycinyl-lactams: a new class of glycine receptor modulator from Australian marine sponges of the genus Psammocinia. Org. Biomol. Chem. 11, 4695–4701. doi: 10.1039/c3ob40861b

Balansa, W., Islam, R., Gilbert, D. F., Fontaine, F., Xiao, X., Zhang, H., et al. (2013b). Australian marine sponge alkaloids as a new class of glycine-gated chloride channel receptor modulator. Bioorg. Med. Chem. 21, 4420–4425. doi: 10.1016/j.bmc.2013.04.061

Belelli, D., Pau, D., Cabras, G., Peters, J. A., and Lambert, J. J. (1999). A single amino acid confers barbiturate sensitivity upon the GABA rho 1 receptor. Br. J. Pharmacol. 127, 601–604. doi: 10.1038/sj.bjp.0702611

Bhattarai, J. P., Cho, D. H., and Han, S. K. (2016). Activation of strychnine-sensitive glycine receptors by shilajit on preoptic hypothalamic neurons of juvenile mice. Chin. J. Physiol. 59, 39–45. doi: 10.4077/CJP.2016.BAE361

Bode, A., and Lynch, J. W. (2014). The impact of human hyperekplexia mutations on glycine receptor structure and function. Mol. Brain 7:2. doi: 10.1186/1756-6606-7-2

Chen, J. T.-c., Guo, D., Campanelli, D., Frattini, F., Mayer, F., Zhou, L., et al. (2014). Presynaptic GABAergic inhibition regulated by BDNF contributes to neuropathic pain induction. Nat. Commun. 5, 5331. doi: 10.1038/ncomms6331

Chung, S. K., Vanbellinghen, J. F., Mullins, J. G., Robinson, A., Hantke, J., Hammond, C. L., et al. (2010). Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia. J. Neurosci. 30, 9612–9620. doi: 10.1523/JNEUROSCI.1763-10.2010

Colborn, T. (2004). Neurodevelopment and endocrine disruption. Environ. Health Perspect. 112, 944–949. doi: 10.1289/ehp.6601

Couillard-Despres, S., Quehl, E., Altendorfer, K., Karl, C., Ploetz, S., Bogdahn, U., et al. (2008). Human in vitro reporter model of neuronal development and early differentiation processes. BMC Neurosci. 9:31. doi: 10.1186/1471-2202-9-31

Coyne, L., Shan, M., Przyborski, S. A., Hirakawa, R., and Halliwell, R. F. (2011). Neuropharmacological properties of neurons derived from human stem cells. Neurochem. Int. 59, 404–412. doi: 10.1016/j.neuint.2011.01.022

Cuddapah, V. A., and Sontheimer, H. (2011). Ion channels and transporters in cancer. 2. Ion channels and the control of cancer cell migration. Am. J. Physiol. Cell Physiol. 301, C541–C549. doi: 10.1152/ajpcell.00102.2011

Deidda, G., Parrini, M., Naskar, S., Bozarth, J. F., Contestabile, A., and Canciedda, L. (2015). Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome. Nat. Med. 21, 318–326. doi: 10.1038/nm.3827

D’Hulst, C., De Geest, N., Reeve, S. P., Van Dam, D., De Deyn, P. P., Hassan, B. A., et al. (2006). Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 1121, 238–245. doi: 10.1016/j.brainres.2006.08.115

Eichler, S. A., Forsteria, B., Smolinsky, B., Juttner, R., Lehmann, T. N., Fahlng, M., et al. (2009). Splice-specific roles of glycine receptor alpha3 in the hippocampus. Eur. J. Neurosci. 30, 1077–1091. doi: 10.1111/j.1460-9586.2009.06903.x
Insecticide Fipronil—a GABAA-Gated Chloride Channel Blocker. J. Toxicol. Clin. Toxicol. 42, 955–963. doi: 10.1080/10603530390210889

Munir, M., Lu, L., Wang, Y. H., Luo, J., Wolfe, B. B., and McGonigle, P. (1996). Pharmacological and immunological characterization of N-methyl-D-aspartate receptors in human NT2-N neurons. J. Pharmacol. Exp. Ther. 276, 819–828.

Narahashi, T. (1996). Neuronal ion channels as the target sites of insecticides. Pharmacol. Ther. 79, 1–14. doi: 10.1016/0168-3659(96)00244-x

Narahashi, T. (2002). Nerve membrane ion channels as the target site of insecticides. Mini. Rev. Med. Chem. 2, 419–432. doi: 10.2174/13895570234054927

Neelands, T. R., Vogel, S. M., and Narahashi, T. (1988). Lindane but not deltamethrin blocks a component of GABA-activated chloride channels. FASEB J. 2, 2895–2900.

Olsen, R. W., and Sieghart, W. (2009). GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 56, 141–148. doi: 10.1016/j.neuropharm.2008.07.045

Oxden, H. (2007). Inducible functional expression of Bcl-2 in human astrocytes derived from NTera-2 cells. J. Neurosci. Methods 159, 8–18. doi: 10.1016/j.jneumeth.2006.06.008

Palocci, G., Fabbri, M., Sacco, M. G., Grilli, L., Parnini, D., Laurenza, I., et al. (2013). mRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicology testing. Cell Biol. Toxicol. 29, 239–257. doi: 10.1007/s10565-013-9250-5

Pleasure, S. J., Page, C., and Lee, V. M. (1992). Pure, postmitotic, polarized human embryonal carcinoma stem cells and the development of neural subtypes. Stem Cells 21, 248–256. doi: 10.1006/stem.21.3–248

Pollett, B., Tüller, A., Schmidt, M., Nazar, A., Tsukamoto, T., Moore, B. A., et al. (2011). Anti-Inflammatory Role of Glycin in Reducing Rodent Postoperative Inflammatory Illus. Neurotoxicology 32, 76–87. doi: 10.1111/j.1365-2980.2010.01630.x

Sun, H., and Machu, T. K. (2000). Bicuculline antagonizes 5-HT(3A) and alpha2 glycine receptors expressed in Xenopus oocytes. Eur. J. Pharmacol. 391, 243–249. doi: 10.1016/S0044-2990(00)00838-2

Suñol, C., Tusell, J. M., Gelpí, E., and Rodríguez-Farré, E. (1989). GABAAergic modulation of lindane (γ-hexachlorocyclohexane)-induced seizures. Toxicol. Appl. Pharmacol. 100, 1–8.

Talwar, S., Lynch, J. W., and Gilbert, D. F. (2013). Fluorescence-based high-throughput functional profiling of ligand-gated ion channels at the level of single cells. PLoS ONE 8, e65847. doi: 10.1371/journal.pone.0065847

Tukker, A. M., de Groot, M. W., Wijnolts, F. M., Kasteel, E. E., Hondebrink, L., and Westerink, R. H. (2016). Is the time right for in vivo neurotoxicity testing using human iPSC-derived neurons? ALTEX. doi: 10.14573/altex.15100991 (Epub ahead of print).

Vafa, B., Lewis, T. M., Cunningham, A. M., Jacques, P., Lynch, J. W., and Schofield, P. R. (1999). Identification of a new ligand binding domain in the alpha1 subunit of the inhibitory glyceric receptor. J. Neurochem. 73, 2158–2166.

Vale, C., Fonfra, E., Bujons, J., Messeguer, A., Rodríguez-Farr, E., and Suol, C. (2003). The organochlorine pesticides γ-hexachlorocyclohexane (lindane), α- endosulfan and dieldrin differentially interact with GABA A and glycine-gated chloride channels in primary cultures of cerebellar granule cells. Neuroscience 117, 397–403. doi: 10.1016/S0306-4522(02)00875-8

Walikz, M. P., Vollmar, V., Lachnit, T., Dietz, H., Haug, S., Bachmann, H., et al. (2015). A portable low-cost long-term live-cell imaging platform for biomedical research and education. Biosens. Bioelectron. 64, 639–649. doi: 10.1016/j.bios.2014.09.061

Wang, D. S., Buckinx, R., Locerronc, H., Mangin, J. M., Rigo, J. M., and Legendre, P. (2007). Mechanisms for picrotoxinin and picrotin blocks of alpha2 homomeric glycine receptors. J. Biol. Chem. 282, 16016–16035. doi: 10.1074/jbc.M701522000

Webb, T. L., and Lynch, J. W. (2007). Molecular pharmacology of the glycine receptor chloride channel. Curr. Pharm. Des. 13, 2350–2367. doi: 10.2174/138161207781368693

Wilhelm, F., Winkler, U., Morawski, M., Jager, C., Reinecke, L., Rossner, M. J., et al. (2011). The human ubiquitin C promoter drives selective expression in principal neurons in the brain of a transgenic mouse line. Neurochem. Int. 59, 976–980. doi: 10.1111/j.1365-2469.2011.04070.x

Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S.-R., Willenbring, D., et al. (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. J. Exp. Med. 209, 1121–1134. doi: 10.1084/jem.20120242

Zeilhofer, H. U. (2005). The glycinergic control of spinal pain processing. Cell. Mol. Life Sci. 62, 2027–2035. doi: 10.1007/s00018-005-1507-2

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.